Checkpoint Therapeutics Inc (CKPT) - Total Assets
Based on the latest financial reports, Checkpoint Therapeutics Inc (CKPT) holds total assets worth $34.16 Million USD as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check CKPT cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Checkpoint Therapeutics Inc - Total Assets Trend (2014–2024)
This chart illustrates how Checkpoint Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Check tangible equity quality of Checkpoint Therapeutics Inc to evaluate the tangible quality of the company's equity base.
Checkpoint Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Checkpoint Therapeutics Inc's total assets of $34.16 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 88.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Checkpoint Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Checkpoint Therapeutics Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Checkpoint Therapeutics Inc's current assets represent 100.0% of total assets in 2024, an increase from 0.0% in 2014.
- Cash Position: Cash and equivalents constituted 88.4% of total assets in 2024, up from 0.0% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Checkpoint Therapeutics Inc Competitors by Total Assets
Key competitors of Checkpoint Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Checkpoint Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.91 | 0.54 | 2.94 |
| Quick Ratio | 1.91 | 0.54 | 2.94 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $16.30 Million | $-10.25 Million | $14.97 Million |
Checkpoint Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Checkpoint Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 22.75 |
| Latest Market Cap to Assets Ratio | 49.22 |
| Asset Growth Rate (YoY) | 38.9% |
| Total Assets | $7.47 Million |
| Market Capitalization | $367.72 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Checkpoint Therapeutics Inc's assets at a significant premium (49.22x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Checkpoint Therapeutics Inc's assets grew by 38.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Checkpoint Therapeutics Inc (2014–2024)
The table below shows the annual total assets of Checkpoint Therapeutics Inc from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $7.47 Million | +38.92% |
| 2023-12-31 | $5.38 Million | -59.53% |
| 2022-12-31 | $13.29 Million | -76.15% |
| 2021-12-31 | $55.73 Million | +30.83% |
| 2020-12-31 | $42.60 Million | +57.96% |
| 2019-12-31 | $26.97 Million | +8.30% |
| 2018-12-31 | $24.90 Million | +16.28% |
| 2017-12-31 | $21.41 Million | -40.48% |
| 2016-12-31 | $35.98 Million | -28.97% |
| 2015-12-31 | $50.65 Million | -- |
| 2014-12-31 | $0.00 | -- |
About Checkpoint Therapeutics Inc
Checkpoint Therapeutics, Inc., a commercial -stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is UNLOXCYT, which is in Phase 1 clinical trial to treat patients with selected recurrent or m… Read more